Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5, 1 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Cardiovascular, Infectious Disease, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Respiratory, Genetic Disorders and Other Diseases which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Inflammation, Myasthenia Gravis, Sepsis, Age Related Macular Degeneration, Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Inflammation, Intermediate Uveitis, Lupus Nephritis, Posterior Uveitis, Septic Shock, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bacterial Pneumonia, Bacterial Sepsis, Benign Mucous Membrane Pemphigoid (Oral Cicatricial Pemphigoid), Bullous Pemphigoid, Cardiovascular Inflammation, Community Acquired Pneumonia, Duchenne Muscular Dystrophy, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Guillain-Barre Syndrome, Hidradenitis Suppurativa, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Kidney Transplant Rejection, Lung Injury, Multiple Organ Failure, Neuromyelitis Optica (Devic's Syndrome), Peritonitis, Polypoidal Choroidal Vasculopathy, Pulmonary Edema, Sicca Syndrome (Sjogren), Thrombotic Microangiopathy, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Uveitis and Wet (Neovascular / Exudative) Macular Degeneration. The latest report Complement C5 - Pipeline Review, H2 2017, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects - The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview 9 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 16 Products under Development by Universities/Institutes 21 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment 23 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development 28 Akari Therapeutics Plc 28 Alexion Pharmaceuticals Inc 28 Alnylam Pharmaceuticals Inc 29 Amgen Inc 29 F. Hoffmann-La Roche Ltd 30 InflaRx GmbH 30 ISU ABXIS Co Ltd 31 Novartis AG 31 NovelMed Therapeutics Inc 32 Noxxon Pharma AG 32 Ophthotech Corp 33 Ra Pharmaceuticals Inc 33 Regeneron Pharmaceuticals Inc 34 Swedish Orphan Biovitrum AB 35 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles 36 AcPepA - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 avacincaptad pegol sodium - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Bikaciomab - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 cemdisiran - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Coversin - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Coversin LA - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 eculizumab - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 eculizumab biosimilar - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 eculizumab biosimilar - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 IFX-1 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 IFX-2 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Mubodina - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 NM-9405 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 NOXD-19 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 NOXD-20 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 NOXD-21 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Protein to Inhibit Complement C5 for Immunology - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 RA-101295 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 RA-101348 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 RA-101495 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 ravulizumab - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 REGN-3918 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 RG-6107 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 SOBI-005 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Synthetic Coversin - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 tesidolumab - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products 92 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products 94 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones 95 Featured News & Press Releases 95 Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 95 Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 95 Sep 19, 2017: Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases 96 Sep 13, 2017: Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis 96 Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa 98 Aug 21, 2017: European Commission Grants New Indication for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) 99 Aug 15, 2017: Alexion Receives Three New U.S. Patents for Soliris (eculizumab), Extending Patent Protection Into 2027 99 Jul 31, 2017: Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 100 Jul 26, 2017: Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases, Provides Update on Zimura 100 Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis 102 Jun 27, 2017: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH 102 Jun 24, 2017: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association 103 Jun 23, 2017: Alexion Receives Positive CHMP Opinion for Soliris for the Treatment of Patients with Refractory Generalized Myasthenia Gravis in the European Union 104 Jun 21, 2017: Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH 105 May 18, 2017: Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association 105 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107
List of Tables
Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15 Number of Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20 Number of Products under Investigation by Universities/Institutes, H2 2017 21 Products under Investigation by Universities/Institutes, H2 2017 22 Number of Products by Stage and Mechanism of Actions, H2 2017 23 Number of Products by Stage and Route of Administration, H2 2017 25 Number of Products by Stage and Molecule Type, H2 2017 27 Pipeline by Akari Therapeutics Plc, H2 2017 28 Pipeline by Alexion Pharmaceuticals Inc, H2 2017 29 Pipeline by Alnylam Pharmaceuticals Inc, H2 2017 29 Pipeline by Amgen Inc, H2 2017 30 Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 30 Pipeline by InflaRx GmbH, H2 2017 31 Pipeline by ISU ABXIS Co Ltd, H2 2017 31 Pipeline by Novartis AG, H2 2017 32 Pipeline by NovelMed Therapeutics Inc, H2 2017 32 Pipeline by Noxxon Pharma AG, H2 2017 33 Pipeline by Ophthotech Corp, H2 2017 33 Pipeline by Ra Pharmaceuticals Inc, H2 2017 34 Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 34 Pipeline by Swedish Orphan Biovitrum AB, H2 2017 35 Dormant Products, H2 2017 92 Dormant Products, H2 2017 (Contd..1), H2 2017 93 Discontinued Products, H2 2017 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
